InvestorsHub Logo
Followers 253
Posts 27820
Boards Moderated 1
Alias Born 08/26/2015

Re: Millstone post# 25345

Wednesday, 10/21/2015 7:18:42 PM

Wednesday, October 21, 2015 7:18:42 PM

Post# of 462996
I had heard it mentioned while monitoring the DVAX and NYMX and IDRA boards. I read the SA article by DR. ke. I read all the scientific stuff. I am a neuroanesthesiologist so understand it to a degree. I have some business and stock experience but nothing special. I had only been in small, individual biotechs for a couple of months. But the science spoke to me as did the confluence of huge market for ALZ, the completely lack of ineffective treatments and the devastation caused with costs in the hundreds of billions per year around the world and soon to be trillions. Been buying since .80 every since. From a pragmatic perspective, I just cannot see how Dr. Missling would put together such a public and large scale team to present anything but extraordinary data. If this second set of data is as good, it is exponentially better as time to effect and scale of effect matters. If 32 patients show the same, this thing IMO goes parabolic because that is what the FDA needs. They also have the best study design guy in the world. I consider missling to be absolutely attuned to the success of AVXL in the long term and maximizing his and investor value.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News